Evidence
J Alzheimers Dis. 2024 Jun 7. doi: 10.3233/JAD-240260. Online ahead of print.
ABSTRACT
BACKGROUND: The identification of biomarkers for different dementias in plasma and cerebrospinal fluid (CSF) has made substantial progress. However, they are observational studies, and there remains a lack of research on dementias with low incidence rates.
OBJECTIVE: We performed a comprehensive Mendelian randomization to identify potential biomarkers for different dementia type.
METHODS: The summary-level datasets encompassed 734 plasma and 154 cerebrospinal fluid proteins sourced from recently published genome-wide association studies (GWAS). Summary statistics for different dementias, including any dementia (refering to any type of dementia symptoms, 218,792 samples), Alzheimer’s disease (AD, 63,926 samples), vascular dementia (212,389 samples), frontotemporal dementia (3,024 samples), dementia with Lewy bodies (DLB, 6,618 samples), and dementia in Parkinson’s disease (216,895 samples), were collected from large GWAS. The primary method is inverse variance weighting, with additional sensitivity analyses conducted to ensure the robustness of the findings.
RESULTS: The molecules released into CSF, namely APOE2 for any dementia, APOE2 and Siglec-3 for AD, APOE2 for vascular dementia, and APOE2 for DLB, might be potential biomarkers. CD33 for AD and SNCA for DLB in plasma could be promising biomarkers.
CONCLUSIONS: This is the first study to integrate plasma and CSF proteins to identify potential biomarkers for different dementias.
PMID:38875042 | DOI:10.3233/JAD-240260
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Exploring Psychosis in Neurodegenerative Dementia: Connecting Symptoms to Neurobiology
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Prevalence and Determinants of Diagnosed Dementia: A Registry Linkage Study Linking Diagnosis of Dementia in the Population-Based HUNT Study to Registry Diagnosis of Dementia in Primary Care and Hospitals in Norway
- Uncovering novel drug targets for bipolar disorder: a Mendelian randomization analysis of brain, cerebrospinal fluid, and plasma proteomes
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- TOPMed imputed genomics enhances genomic atlas of the human proteome in brain, cerebrospinal fluid, and plasma
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Could the Historical Transition from Segmented to Monophasic Sleep Explain the Modern Insurgence of Alzheimer's Disease and Related Dementias?
- Cerebrospinal fluid synaptic biomarker changes in bipolar disorder - A longitudinal case-control study
- Plasma BDNF/Irisin Ratio Associates with Cognitive Function in Older People
- Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis
- Cerebrospinal fluid a-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults
- Cerebrospinal fluid amyloid-β and cerebral microbleed are associated with distinct neuropsychiatric sub-syndromes in cognitively impaired patients
- A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function
- Psychosis in Neurodegenerative Dementias: A Systematic Comparative Review
- Systematic Review of Cerebrospinal Fluid Biomarker Discovery in Neuro-Oncology: A Roadmap to Standardization and Clinical Application
- Genetic evidence for the causal relationships between migraine, dementia, and longitudinal brain atrophy
- Biomarkers of neurodegeneration in schizophrenia: systematic review and meta-analysis
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Forecasting the 20-Year Incidence of Dementia by Socioeconomic Status, Race/Ethnicity, and Region Based on Mid-Life Risk Factors in a U.S. Nationally Representative Sample
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers
- Synaptic vesicle glycoprotein 2 A in serum is an ideal biomarker for early diagnosis of Alzheimer's disease
- Mediating and moderating effects of plasma proteomic biomarkers on the association between poor oral health problems and incident dementia: The UK Biobank study
- Resting heart rate and risk of dementia: a Mendelian randomization study in the international genomics of Alzheimer's Project and UK Biobank
- Neuroforensomics: metabolites as valuable biomarkers in cerebrospinal fluid of lethal traumatic brain injuries
- Pimavanserin's Safety Profile: Insights from a Phase 3b Clinical Trial
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Protocol to characterize immune cell subpopulations in cerebrospinal fluid of patients with neuroinflammatory diseases using mass cytometry
- Protocol to characterize immune cell subpopulations in cerebrospinal fluid of patients with neuroinflammatory diseases using mass cytometry
- Association of Cancer History with Lifetime Risk of Dementia and Alzheimer's Disease
- Associations of hospital-treated infections with subsequent dementia: nationwide 30-year analysis
- Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy
- Vitamin D, Alzheimer's disease and related dementia
- Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial
- Bidirectional two-sample Mendelian randomization analyses support causal relationships between structural and diffusion imaging-derived phenotypes and the risk of major neurodegenerative diseases
- Characterization of HIV variants from paired Cerebrospinal fluid and Plasma samples in primary microglia and CD4+ T-cells
- Characterization of HIV variants from paired Cerebrospinal fluid and Plasma samples in primary microglia and CD4+ T-cells
- Echocardiographic measures of the left heart and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact adults: The CABLE study
- Biochemical, Biomarker, and Behavioral Characterization of the GrnR493X Mouse Model of Frontotemporal Dementia
- Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS)
- Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
- Plasma biomarkers increase diagnostic confidence in patients with Alzheimer's disease or frontotemporal lobar degeneration
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy
- Ubiquity of Synthetic Phenolic Antioxidants in Children's Cerebrospinal Fluid from South China: First Evidence for Their Penetration across the Blood-Cerebrospinal Fluid Barrier
- New knowledge on anti-IgLON5 disease
- Comparison of plasma and neuroimaging biomarkers to predict cognitive decline in non-demented memory clinic patients
- Automatic classification of AD pathology in FTD phenotypes using natural speech
- Causal relationship between dietary salt intake and dementia risk: Mendelian randomization study
- Addition of inflammation-related biomarkers to the CAIDE model for risk prediction of all-cause dementia, Alzheimer's disease and vascular dementia in a prospective study
- Incidence and Risk Factors Epilepsy in Patients with Dementia: A Population-Based Study Using Regional Healthcare Databases in Umbria
- Adaptive immune changes associate with clinical progression of Alzheimer's disease
- Genetically Determined Plasma Hepatocyte Growth Factor Levels Are Associated With the Risk and Prognosis of Ischemic Stroke
Evidence Blueprint
Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Potential Biomarkers in Cerebrospinal Fluid and Plasma for Dementia
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts
- A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
- Potential Utility of Plasma Biomarker Panels in Differential Diagnosis of Alzheimer's Disease
- Exploring Psychosis in Neurodegenerative Dementia: Connecting Symptoms to Neurobiology
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Proteome Network Analysis Identifies Potential Biomarkers for Brain Aging
- The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa
- Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population-based study
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Association of amyloid-beta with depression or depressive symptoms in older adults without dementia: a systematic review and meta-analysis
- Characteristics of T Cells in Single-Cell Datasets of Peripheral Blood and Cerebrospinal Fluid in Alzheimer's Disease Patients
- Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
- Prevalence and Determinants of Diagnosed Dementia: A Registry Linkage Study Linking Diagnosis of Dementia in the Population-Based HUNT Study to Registry Diagnosis of Dementia in Primary Care and Hospitals in Norway
- Uncovering novel drug targets for bipolar disorder: a Mendelian randomization analysis of brain, cerebrospinal fluid, and plasma proteomes
- Plasma biomarkers for predicting the development of dementia in a community-dwelling older Japanese population
- Investigating the association between a history of depression and biomarkers of Alzheimer's disease, cerebrovascular disease, and neurodegeneration in patients with dementia
- Associations between liver function and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in non-demented adults: The CABLE study
- Differential Associations of APOEɛ2 and APOEɛ4 Genotypes with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease in Individuals Without Dementia
- Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy
- Use of modern classification systems for complex diagnostics of Alzheimer's disease
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats during EEG Recordings
- Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression
- Plasma and cerebrospinal fluid concentrations of neurofilament light protein correlate in patients with idiopathic normal pressure hydrocephalus
- Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms
- Biomarkers of Alzheimer's disease and neurodegeneration in dried blood spots-A new collection method for remote settings
- Plasma Phosphorylated Tau 231 Increases at One-Year Intervals in Cognitively Unimpaired Subjects
- Gut microbiota, circulating cytokines and dementia: a Mendelian randomization study
- Day-to-day sleep variability with Alzheimer's biomarkers in at-risk elderly
- ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium
- Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias
- TOPMed imputed genomics enhances genomic atlas of the human proteome in brain, cerebrospinal fluid, and plasma
- Plasma Amyloid-β, Total Tau, and Neurofilament Light Chain Across the Alzheimer's Disease Clinical Spectrum: A Population-Based Study
- Genome-wide analysis identifies novel loci influencing plasma apolipoprotein E concentration and Alzheimer's disease risk
- Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force
- Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
- Mechanisms behind changes of neurodegeneration biomarkers in plasma induced by sleep deprivation
- Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease
- Association of COVID-19 with Risk and Progression of Alzheimer's Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects
- Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
- Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia
- Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease
- Identification and quantification of (poly)phenol and methylxanthine metabolites in human cerebrospinal fluid: evidence of their ability to cross the BBB
- The use of synaptic biomarkers in cerebrospinal fluid to differentiate behavioral variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease
- High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease
- Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid
- Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP)
- Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Search for cerebrospinal fluid biomarkers in patients with major psychiatric disorders: Multiplex immunoassay findings and proximity extension assay prospects
- Multimorbidity, cognitive phenotypes, and Alzheimer's disease plasma biomarkers in older adults: A population-based study
- Human cerebrospinal fluid contains diverse lipoprotein subspecies enriched in proteins implicated in central nervous system health
- Associations of cerebrospinal fluid complement proteins with Alzheimer's pathology, cognition, and brain structure in non-dementia elderly
- Total Tau Protein Mediates the Association of Ischemic Cerebrovascular Disease with Cognitive Decline
- Could the Historical Transition from Segmented to Monophasic Sleep Explain the Modern Insurgence of Alzheimer's Disease and Related Dementias?
- miRNAs in cerebrospinal fluid associated with Alzheimer's disease: A systematic review and pathway analysis using a data mining and machine learning approach
- Tear biomarkers for Alzheimer's disease screening and diagnosis (the TearAD study): design and rationale of an observational longitudinal multicenter study
- Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease